Sweden Pharmaceutical Market

ID: MRFR/Pharma/20196-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Sweden Pharmaceutical Market Research Report Information By Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatological Drugs, Genitourinary System, Reproductive Hormones, Systemic Hormonal Preparations, Immunomodulating Agents, Musculoskeletal System, Nervous System, Ant parasitic Products, Insecticides and Repellents, Respiratory System, Sensory Organs, Various ATC Structures), By Drug Type (Branded, Generic) By Prescription Type (Prescription Drugs (Rx), OTC Drugs) – Sweden’s Market Forecast Till 2035
Sweden Pharmaceutical Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.21%
2024 Market Size$ 465.5 Billion
2025 Market Size$ 481.98 Billion
2035 Market Size$ 659.18 Billion
Key Players
Roche
Novartis
Sanofi
Bayer
GlaxoSmithKline
AstraZeneca
Trends
  • Rise of Biopharmaceuticals
  • Digital Health Integration
  • Regulatory Evolution
Opportunities
  • Aging Population
  • Technological Advancements
  • Rising Demand for Generic Drugs
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Therapeutic Area (USD Billion)
      1. 4.1.1 Cardiovascular
      2. 4.1.2 Oncology
      3. 4.1.3 Neurology
      4. 4.1.4 Diabetes
      5. 4.1.5 Infectious Disease
    2. 4.2 Healthcare, BY Drug Type (USD Billion)
      1. 4.2.1 Prescription Drug
      2. 4.2.2 Over-the-Counter Drug
      3. 4.2.3 Biologics
      4. 4.2.4 Generics
      5. 4.2.5 Orphan Drug
    3. 4.3 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.3.1 Hospital Pharmacy
      2. 4.3.2 Retail Pharmacy
      3. 4.3.3 Online Pharmacy
      4. 4.3.4 Specialty Pharmacy
      5. 4.3.5 Wholesalers
    4. 4.4 Healthcare, BY Formulation Type (USD Billion)
      1. 4.4.1 Tablet
      2. 4.4.2 Injection
      3. 4.4.3 Topical
      4. 4.4.4 Liquid
      5. 4.4.5 Capsule
    5. 4.5 Healthcare, BY End User (USD Billion)
      1. 4.5.1 Hospitals
      2. 4.5.2 Clinics
      3. 4.5.3 Homecare
      4. 4.5.4 Pharmacies
      5. 4.5.5 Research Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 GlaxoSmithKline (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck KGaA (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Boehringer Ingelheim (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AbbVie (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 Pfizer (US)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
    3. 6.3 EUROPE MARKET ANALYSIS BY DRUG TYPE
    4. 6.4 EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 EUROPE MARKET ANALYSIS BY FORMULATION TYPE
    6. 6.6 EUROPE MARKET ANALYSIS BY END USER
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
      2. 7.2.2 BY DRUG TYPE, 2026-2035 (USD Billion)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
      4. 7.2.4 BY FORMULATION TYPE, 2026-2035 (USD Billion)
      5. 7.2.5 BY END USER, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Europe Sweden Pharmaceutical Market Segmentation

Sweden Pharmaceutical Market By Therapeutic Area (USD Billion, 2026-2035)

  • Cardiovascular
  • Oncology
  • Neurology
  • Diabetes
  • Infectious Disease

Sweden Pharmaceutical Market By Drug Type (USD Billion, 2026-2035)

  • Prescription Drug
  • Over-the-Counter Drug
  • Biologics
  • Generics
  • Orphan Drug

Sweden Pharmaceutical Market By Distribution Channel (USD Billion, 2026-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Specialty Pharmacy
  • Wholesalers

Sweden Pharmaceutical Market By Formulation Type (USD Billion, 2026-2035)

  • Tablet
  • Injection
  • Topical
  • Liquid
  • Capsule

Sweden Pharmaceutical Market By End User (USD Billion, 2026-2035)

  • Hospitals
  • Clinics
  • Homecare
  • Pharmacies
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.